Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis
Key facts
- Who runs it
- University of Virginia
- Where
- Charlottesville, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 76 people enrolled
- Started
- 2 Aug 2021
- Ended
- 30 Jun 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Cosyntropin
- Record updated
- 10 December 2024
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Age >= 18y
- Diagnosis of cirrhosis by biopsy or compatible clinical picture
- Experienced at least one portal decompensating event in the past and currently have a Child-Pugh B or C classification
Who cannot take part
- Not been treated with medication known to affect the adrenal axis within the past 4 weeks (oral or IV steroids, ketoconazole, etomidate)
- Pregnant women
- Prisoners
- Hospitalized at time of enrollment
Where in United States
- University of Virginia Health SystemCharlottesville, United States
About the trial
What the trial wants to find out
This study aims to define the prevalence and potential pathophysiologic mechanisms underlying relative adrenal insufficiency (RAI) in outpatients with decompensated cirrhosis. Patients will be followed prospectively for up to two years to determine incidence of RAI, whether RAI represents a permanent or dynamic physiologic state in cirrhosis, and to determine whether RAI in this setting is associated with important clinical outcomes.
The 2 groups in the trial
- RAI
Subjects will be diagnosed with relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol \<9mcg/dL.
Treatment: Cosyntropin
- Non-RAI
Subjects will have not have relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol \>= 9mcg/dL.
Treatment: Cosyntropin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Defining the Mechanisms Underlying Adrenal Dysfunction in Cirrhosis and Its Prognostic Significance
- Record updated
- 10 December 2024